Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers
Reuters2026/08/09 12:41- Silexion highlighted SIL204, a second-generation siRNA designed to silence KRAS expression in KRAS-driven solid tumors, including PDAC, CRC, NSCLC.
- Phase 2/3 program launched for locally advanced pancreatic cancer using dual delivery: intratumoral dosing for primary tumors, subcutaneous dosing for micrometastases.
- Primary endpoint is overall survival; secondary endpoints include ctDNA biomarkers expected early Q4 2026, progression-free survival, overall response rate.
- Trial plan calls for a safety run-in completing Q2 2027, a Phase 2 expansion starting Q3 2027, a Phase 3 confirmatory stage starting Q3 2030.
- Company cited a total addressable market of USD 2 billion in the U.S., USD 3 billion in the EU for localized advanced pancreatic cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After Waller's hawkish speech, the market focuses on "rate hikes", but Morgan Stanley says balance sheet reduction is more likely.
After the Jackson Hole meeting, the market's focus has shifted to interest rate hike expectations. However, Morgan Stanley economist Carpenter pointed out that Walsh's long-standing stance on reducing the $7 trillion balance sheet should not be overlooked. It is expected that the Federal Reserve may begin a balance sheet reduction of more than $1.5 trillion next year, partially replacing rate hikes.
BTC surpasses $78,000
AON plans to acquire USI for 17 billion USD, aiming at the SME insurance brokerage market.
According to informed sources, AON.US is close to reaching a deal valued at around $17 billion, including debt, to acquire insurance brokerage USI from private equity firm KKR.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
